Advertisement
Under the terms of the agreement, the University of Washington will expandits recruitment of leading institutions world-wide to participate in buildingcomprehensive databases of right and left ventricle reconstructionsrepresenting specific heart diseases, such as congenital heart disease (CHD).These databases will be referenced by the VDS as it delivers three-dimensionalmodels and analysis of patients' hearts based on anatomical points identifiedby doctors on two-dimensional scans.
Advertisement
"Our core technology was first developed at the University of Washington,so it makes sense to collaborate with their subject matter experts," saidJoseph Ashley, CEO of VentriPoint Diagnostics. "The results of these projectswill enhance and speed the commercial development of the VentriPointDiagnostic System, which uses existing medical imaging systems to generatecritical heart measurements in a rapid and inexpensive manner not currentlyavailable."
Under the agreement, the University of Washington will collaborate withVentriPoint to increase the size of the database used by the VDS by up to 160additional CHD heart reconstructions of different conditions. The Universityof Washington will also continue its transition of knowledge and processes toVentriPoint, in support of the technology license. It will also commencerecruitment of patients with pulmonary hypertension to begin development of asubsequent VDS application. Financial terms of the agreement were notdisclosed.
About VentriPoint Diagnostics
VentriPoint creates diagnostic tools to monitor patients with heartdisease -- the number one cause of death in developed countries. By usingexisting medical imaging systems, the VentriPoint Diagnostic System generatescritical heart measurements in a rapid and inexpensive manner not currentlyavailable. This breakthrough diagnostic tool is based upon VentriPoint'stechnology license with the University of Washington. The VentriPointDiagnostic System, together with its associated online service, is beingdeveloped for a variety of heart related disease states, including congenitalheart disease.
The TSX Venture Exchange has not reviewed and does not acceptresponsibility for the adequacy or accuracy of this release.For further information, please contact: Edward Garth, Chief Financial Officer VentriPoint Diagnostics Ltd. Telephone: (206) 283-0221, ext. 402 Facsimile: (206) 283-2309 VentriPoint Media Contacts: Russo Partners LLC Ian Stone (619) 814-3510 [email protected]
SOURCE VentriPoint Diagnostics Ltd.
